Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of asciminib (ABL001) versus bosutinib in previously treated chronic-phase chronic myeloid leukemia
MOH_2017-07-17_000398Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Asciminib with Bosutinib (2 arms). Primary endpoint: Major molecular response at 24 weeks. Started Jun 2017; status: active, not recruiting.
02
Drugs
asciminibbosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on MOH_2017-07-17_000398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-17_000398.